Omnia Biologics and University of Maryland Bioprocess Scale-Up Facility Cooperate in Providing Biopharmaceutical Processing And Manufacture.
ROCKVILLE, Md. -- Biologics contract manufacturer Omnia Biologics, Inc. (Rockville, MD) and University of Maryland University of Maryland can refer to:
"The opportunity to collaborate with the world's premier academic bioprocessing facility is a great asset to our customers." commented Dale VanderPutten, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Omnia Biologics "The combination of the BSF scale-up fermentation and training expertise and Omnia's cGMP processes, class 100 sterile fill-finish, and BSL-3 suites provides a unique resource to biotech and academic investigators and reinforces Maryland as a leader in biotechnology." The BSF is the University of Maryland Biotech Program's modern bioprocessing laboratory dedicated to the development and scale-up of biotechnology products and processes. With more than 678 fermentations conducted since 1998 alone, the BSF has accelerated the R&D of local biotechnology leaders such as Human Genome Sciences Human Genome Sciences NASDAQ: HGSI is a biopharmaceutical corporation founded in 1992. Its stated purpose is to "discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs. , NIH "Not invented here." See digispeak.
NIH - The United States National Institutes of Health. and MedImmune, as well as growing Maryland start-ups such as Martek Biosciences and Digene Corporation.
About Omnia Biologics: (www.omniabiologics.com)
Omnia offers services in the areas of process development, GMP GMP (guanosine monophosphate): see guanine. manufacture, and fill-finish for preclinical and Phase I clinical programs for therapeutics that do not have effective or known manufacturing protocols. These include autologous therapeutics, new gene therapeutic platforms, and stem cell technologies. The company seeks and has established relationships with both biopharmaceutical companies and academic investigators throughout the world.